168 related articles for article (PubMed ID: 31107859)
1. Expression of WD Repeat Domain 5 (WDR5) is Associated with Progression and Reduced Prognosis in Papillary Thyroid Carcinoma.
Xu W; Wang L; An Y; Ye J
Med Sci Monit; 2019 May; 25():3762-3770. PubMed ID: 31107859
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of WD repeat domain 5 associates with aggressive clinicopathological features and unfavorable prognosis in head neck squamous cell carcinoma.
Wu Y; Diao P; Li Z; Zhang W; Wang D; Wang Y; Cheng J
J Oral Pathol Med; 2018 May; 47(5):502-510. PubMed ID: 29569374
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Xu W; Chen F; Fei X; Yang X; Lu X
Med Sci Monit; 2018 Oct; 24():7357-7365. PubMed ID: 30319138
[TBL] [Abstract][Full Text] [Related]
4. Histone methyltransferase KMT5A gene modulates oncogenesis and lipid metabolism of papillary thyroid cancer in vitro.
Liao T; Wang YJ; Hu JQ; Wang Y; Han LT; Ma B; Shi RL; Qu N; Wei WJ; Guan Q; Xiang J; Chen JY; Sun GH; Li DS; Mu XM; Ji QH
Oncol Rep; 2018 May; 39(5):2185-2192. PubMed ID: 29512765
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of G Protein-Coupled Receptor Kinase 6 (GRK6) Is Associated with Progression and Poor Prognosis of Papillary Thyroid Carcinoma.
Che X; Zhang G; Zhang X; Xue J
Med Sci Monit; 2018 May; 24():3540-3548. PubMed ID: 29805156
[TBL] [Abstract][Full Text] [Related]
6. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
Jia M; Guo Y; Lu X
Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of lncRNA-ATB by Transforming Growth Factor β1 (TGF-β1) Promotes Migration and Invasion of Papillary Thyroid Carcinoma Cells.
Cui M; Chang Y; Du W; Liu S; Qi J; Luo R; Luo S
Med Sci Monit; 2018 Jul; 24():5152-5158. PubMed ID: 30042377
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-1266 suppresses papillary thyroid carcinoma cell metastasis and growth via targeting FGFR2.
Fu YT; Zheng HB; Zhang DQ; Zhou L; Sun H
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3430-3438. PubMed ID: 29917195
[TBL] [Abstract][Full Text] [Related]
9. miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma.
Qiu Z; Li H; Wang J; Sun C
Oncol Rep; 2017 Nov; 38(5):2735-2740. PubMed ID: 29048684
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and Prognostic Significance of WW Domain Binding Protein 5 Expression in Papillary Thyroid Carcinoma.
Qian Y; Pan Z; Guo Z; Ge X; Zheng G; Cao J; Huang P; Zhu X; Zhu X; Wen Q; Ge M
Biomed Res Int; 2019; 2019():1791065. PubMed ID: 31828091
[TBL] [Abstract][Full Text] [Related]
11.
Wen J; Lin B; Lin L; Chen Y; Wang O
Aging (Albany NY); 2020 Aug; 12(16):16437-16456. PubMed ID: 32857728
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of miR-421 predicts poor prognosis and promotes proliferation, migration, and invasion of papillary thyroid cancer cells.
Dong A; Zhang J; Sun W; Hua H; Sun Y
J Chin Med Assoc; 2020 Nov; 83(11):991-996. PubMed ID: 32881717
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic Ras/squamous cell carcinoma antigen signaling pathway activation promotes invasiveness and lymph node metastases in papillary thyroid carcinoma.
Luo D; Liu Y; Lin S; Tan L; Du Z; Long M; Zhu Y; Peng X; Zong W; Mackenzie GG; Li H; Ouyang N
Oncol Rep; 2019 Feb; 41(2):1253-1263. PubMed ID: 30535496
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
[TBL] [Abstract][Full Text] [Related]
15. Correlations of HOTAIR expression with pathological stage, CT characteristics and prognosis of patients with papillary thyroid carcinoma.
Chen X; Jin J; Zheng L; Sheng Y; Sun J
J BUON; 2021; 26(1):259-265. PubMed ID: 33721460
[TBL] [Abstract][Full Text] [Related]
16. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
[TBL] [Abstract][Full Text] [Related]
17. Silencing long non-coding RNAs nicotinamide nucleotide transhydrogenase antisense RNA 1 inhibited papillary thyroid cancer cell proliferation, migration and invasion and promoted apoptosis via targeting miR-199a-5p.
Wang D; Zheng Y
Endocr J; 2021 May; 68(5):583-597. PubMed ID: 33612561
[TBL] [Abstract][Full Text] [Related]
18. FOXE1 inhibits cell proliferation, migration and invasion of papillary thyroid cancer by regulating PDGFA.
Ding Z; Ke R; Zhang Y; Fan Y; Fan J
Mol Cell Endocrinol; 2019 Aug; 493():110420. PubMed ID: 31129275
[TBL] [Abstract][Full Text] [Related]
19. BGL3 inhibits papillary thyroid carcinoma progression via regulating PTEN stability.
Zhao M; Yang F; Sang C; Yan C; Wang Z
J Endocrinol Invest; 2021 Oct; 44(10):2165-2174. PubMed ID: 33543443
[TBL] [Abstract][Full Text] [Related]
20. Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features.
Gao J; Ma XP; Deng FS; Jiang L; Jia WD; Li M
Pathol Oncol Res; 2020 Jul; 26(3):1833-1841. PubMed ID: 31758408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
